297 related articles for article (PubMed ID: 25311218)
1. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031.
Friedman DL; Chen L; Wolden S; Buxton A; McCarten K; FitzGerald TJ; Kessel S; De Alarcon PA; Chen AR; Kobrinsky N; Ehrlich P; Hutchison RE; Constine LS; Schwartz CL
J Clin Oncol; 2014 Nov; 32(32):3651-8. PubMed ID: 25311218
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
Marks LJ; Pei Q; Bush R; Buxton A; Appel B; Kelly KM; Schwartz CL; Friedman DL
Pediatr Blood Cancer; 2018 Dec; 65(12):e27375. PubMed ID: 30277639
[TBL] [Abstract][Full Text] [Related]
3. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group.
Dharmarajan KV; Friedman DL; Schwartz CL; Chen L; FitzGerald TJ; McCarten KM; Kessel SK; Iandoli M; Constine LS; Wolden SL
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):60-6. PubMed ID: 25542311
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031.
Parzuchowski A; Bush R; Pei Q; Friedman DL; FitzGerald TJ; Wolden SL; Dharmarajan KV; Constine LS; Laurie F; Kessel SK; Appel B; Fernandez K; Punnett A; Schwartz CL; Cox J; Terezakis SA
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1119-1125. PubMed ID: 29722656
[TBL] [Abstract][Full Text] [Related]
5. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.
Kelly KM; Sposto R; Hutchinson R; Massey V; McCarten K; Perkins S; Lones M; Villaluna D; Weiner M
Blood; 2011 Mar; 117(9):2596-603. PubMed ID: 21079154
[TBL] [Abstract][Full Text] [Related]
6. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.
Charpentier AM; Friedman DL; Wolden S; Schwartz C; Gill B; Sykes J; Albert-Green A; Kelly KM; Constine LS; Hodgson DC
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):943-950. PubMed ID: 27869096
[TBL] [Abstract][Full Text] [Related]
7. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group.
Kelly KM; Cole PD; Pei Q; Bush R; Roberts KB; Hodgson DC; McCarten KM; Cho SY; Schwartz C
Br J Haematol; 2019 Oct; 187(1):39-48. PubMed ID: 31180135
[TBL] [Abstract][Full Text] [Related]
8. Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis.
Parekh A; Keller FG; McCarten KM; Kessel S; Cho S; Pei Q; Wu Y; Castellino SM; Constine LS; Schwartz CL; Hodgson D; Kelly KM; Hoppe BS
Blood; 2022 Sep; 140(10):1086-1093. PubMed ID: 35763667
[TBL] [Abstract][Full Text] [Related]
9. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.
Nachman JB; Sposto R; Herzog P; Gilchrist GS; Wolden SL; Thomson J; Kadin ME; Pattengale P; Davis PC; Hutchinson RJ; White K;
J Clin Oncol; 2002 Sep; 20(18):3765-71. PubMed ID: 12228196
[TBL] [Abstract][Full Text] [Related]
11. Pericardial effusion in Hodgkin lymphoma: a report from the Children's Oncology Group AHOD0031 protocol.
Marks LJ; McCarten KM; Pei Q; Friedman DL; Schwartz CL; Kelly KM
Blood; 2018 Sep; 132(11):1208-1211. PubMed ID: 30061157
[No Abstract] [Full Text] [Related]
12. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.
Tebbi CK; Mendenhall NP; London WB; Williams JL; Hutchison RE; Fitzgerald TJ; de Alarcón PA; Schwartz C; Chauvenet A
Pediatr Blood Cancer; 2012 Dec; 59(7):1259-65. PubMed ID: 22911615
[TBL] [Abstract][Full Text] [Related]
13. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.
Schwartz CL; Constine LS; Villaluna D; London WB; Hutchison RE; Sposto R; Lipshultz SE; Turner CS; deAlarcon PA; Chauvenet A
Blood; 2009 Sep; 114(10):2051-9. PubMed ID: 19584400
[TBL] [Abstract][Full Text] [Related]
14. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
16. ABVD or BEACOPP
Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group.
Parikh RR; Kelly KM; Hodgson DC; Hoppe BS; McCarten KM; Karolczuk K; Pei Q; Wu Y; Cho SY; Schwartz C; Cole PD; Roberts K
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(4):890-900. PubMed ID: 34767937
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
19. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.
Schwartz CL; Chen L; McCarten K; Wolden S; Constine LS; Hutchison RE; de Alarcon PA; Keller FG; Kelly KM; Trippet TA; Voss SD; Friedman DL
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786406
[TBL] [Abstract][Full Text] [Related]
20. Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution.
de Armas S; Huertas-Ayala C; Chan RY; Chi YY; Huh WW; Termuhlen A; Gaynon PS; Kovach AE; Doan A
Pediatr Blood Cancer; 2022 May; 69(5):e29601. PubMed ID: 35187850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
